Addition of inavolisib to palbociclib and fulvestrant reduces risk of progression Presented ByProf. Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, INAVO120 ConferenceSABCS 2023 TypeNews article 11 January 2024 14:59